

Research article

Open Access

The role of *CACNA1S* in predisposition to malignant hyperthermia

Danielle Carpenter*¹, Christopher Ringrose¹, Vincenzo Leo¹, Andrew Morris², Rachel L Robinson¹, P Jane Halsall¹, Philip M Hopkins^{†1} and Marie-Anne Shaw^{†3}

Address: ¹MH Investigation Unit, Academic Unit of Anaesthesia, St James's University Hospital, Leeds, LS9 7TF, UK, ²Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK and ³Institute of Integrative and Comparative Biology, LC Miall Building, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK

Email: Danielle Carpenter* - danielle.carpenter@nottingham.ac.uk; Christopher Ringrose - chrisringrose81@hotmail.com; Vincenzo Leo - vincenzoleo1@hotmail.com; Andrew Morris - amorris@well.ox.ac.uk; Rachel L Robinson - r.l.robinson@leeds.ac.uk; P Jane Halsall - p.j.halsall@leeds.ac.uk; Philip M Hopkins - p.m.hopkins@leeds.ac.uk; Marie-Anne Shaw - m.shaw@leeds.ac.uk

* Corresponding author †Equal contributors

Published: 13 October 2009

Received: 28 April 2009

BMC Medical Genetics 2009, 10:104 doi:10.1186/1471-2350-10-104

Accepted: 13 October 2009

This article is available from: <http://www.biomedcentral.com/1471-2350/10/104>

© 2009 Carpenter et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder of skeletal muscle, characterised by an elevated calcium release from the skeletal muscle sarcoplasmic reticulum. The dihydropyridine receptor (DHPR) plays an essential role in excitation-contraction coupling and calcium homeostasis in skeletal muscle. This study focuses on the gene *CACNA1S* which encodes the $\alpha 1$ subunit of the DHPR, in order to establish whether *CACNA1S* plays a major role in MH susceptibility in the UK.

Methods: We investigate the *CACNA1S* locus in detail in 50 independent MH patients, the largest study to date, to identify novel variants that may predispose to disease and also to characterise the haplotype structure across *CACNA1S*.

Results: We present *CACNA1S* cDNA sequencing data from 50 MH patients in whom *RYR1* mutations have been excluded, and subsequent mutation screening analysis. Furthermore we present haplotype analysis of unphased *CACNA1S* SNPs to (1) assess *CACNA1S* haplotype frequency differences between susceptible MH cases and a European control group and (2) analyse population-based association via clustering of *CACNA1S* haplotypes based on disease risk.

Conclusion: The study identified a single potentially pathogenic change in *CACNA1S* (p.Arg174Trp), and highlights that the haplotype structure across *CACNA1S* is diverse, with a high degree of variability.

Background

Malignant hyperthermia (MH) is an inherited disorder of skeletal muscle, which predisposes to an increased release of calcium into the myoplasm under certain pharmaco-

logical conditions. Inhalational anaesthetics and the muscle relaxant suxamethonium can trigger an MH crisis and lead to acceleration of muscle metabolism and contractile activity generating heat and leading to hypoxaemia, met-

abolic acidosis, rhabdomyolysis and a rapid rise in body temperature. This condition is potentially fatal if not recognised and treated promptly.

Biochemical studies have shown that an MH crisis is due to an abnormal cellular calcium homeostasis within the skeletal muscle [1]. Within skeletal muscle the sarcoplasmic reticulum (SR) controls the process of Ca^{2+} release, playing a major role in the process of excitation-contraction (E-C) coupling. During E-C coupling depolarisation of the sarcolemma initiates a conformational change in the voltage-gated Ca^{2+} channel (dihydropyridine receptor (DHPR)) subsequently activating the Ca^{2+} release channel (Ryanodine receptor (RyR1)) to release Ca^{2+} from the SR [2]. During an MH crisis an elevated rate of cellular Ca^{2+} release from the SR is observed due, in part, to a reduced activation and increased deactivation threshold of the RyR1 [3], or from uncoupling of the DHPR-RyR1 interaction [4].

Genetic analyses have demonstrated that MH susceptibility exhibits locus heterogeneity, with significant observations for linkage to chromosome 1q [5,6] and 19q [7,8]. The locus on chromosome 19q has been identified as the gene encoding the skeletal muscle ryanodine receptor (*RYR1*) [8], and that on chromosome 1q as the gene encoding the $\alpha 1$ subunit of the DHPR (*CACNA1S*) [5]. There is a finely balanced interaction between the gene products of *RYR1* and *CACNA1S*, which are only beginning to be understood with alterations in both gene products affecting E-C coupling and modifying Ca^{2+} regulation [3,4].

Much research into MH susceptibility has been focused on the *RYR1* locus and it is recognised that *RYR1* plays a major role in susceptibility to MH. There are now over 178 mis-sense mutations described across *RYR1* that co-segregate with MH susceptibility, 29 of which have been functionally characterised and are used diagnostically (reviewed in [9]). In the UK, *RYR1* plays a part in MH susceptibility in over 70% (394/554) of UK pedigrees. Considerably less, however, is known about *CACNA1S*. Previous studies have demonstrated linkage to chromosome 1q within MH families that show *RYR1* exclusion [10], but to date there is only a single mis-sense change (p.Arg1086His) described in *CACNA1S* in association with MH [5]. This change was first detected in a single extended French family in 12 individuals all diagnosed as susceptible to MH, and absent from the 6 individuals diagnosed as normal [5]. In a North American study of 98 independent MH samples this change was also identified in a single family [11], in 2 from the 5 MH diagnosed individuals. p.Arg1086His was not detected in 100 independent normal French chromosomes [5], nor in 150 unrelated North American normal samples [11]. Interest-

ingly, this change has further been described alongside an *RYR1* alteration (p.Pro4973Leu) in a single individual [12], where the rest of the family diagnosed as MHS were accounted for by either the *RYR1* change (three individuals) or the *CACNA1S* change (two individuals), suggesting a potentially more complex means of MH susceptibility involving multiple gene products.

The aim of this study is to investigate the *CACNA1S* locus in detail and to determine whether *CACNA1S* may play a major role in MH susceptibility in the UK. As targeted sequencing for *RYR1* has led to potential bias in mutation detection, we have sequenced the full cDNA transcript of *CACNA1S* for novel changes in 50 independent MH patients. We report here the findings of this sequencing and subsequent mutation screening. Furthermore, characterisation of the haplotype structure across *CACNA1S* is investigated. We present analysis using unphased *CACNA1S* SNP data directly to (1) assess *CACNA1S* haplotype frequency differences between MH susceptible cases and a population control group and (2) to analyse population-based association via clustering of *CACNA1S* haplotypes based on disease risk.

Methods

In-vitro contracture testing

There is a well defined and standardised protocol for the laboratory confirmation of suspected MH cases and testing of family members. The *in vitro* contracture test (IVCT) involves exposure of skeletal muscle biopsy specimens to incremental concentrations of halothane or caffeine in an irrigated tissue bath and the subsequent measurement of muscle contracture in response to the applied stimulants. All individuals were phenotyped by the IVCT according to the European MH Group (EMHG) guidelines <http://www.emhg.org> at the MH Investigation Unit at St James's Hospital, Leeds, UK. The European protocol assigns the patient to one of three laboratory diagnostic categories, MHS, MHN or MHE according to whether their muscle displays increased sensitivity to both, none or only one of the stimulants respectively. Both MHS and MHE categories are deemed to represent clinical susceptibility to MH.

Samples

This study utilises the largest worldwide resource of genotyped MH samples from patients phenotyped in a single diagnostic centre. *CACNA1S* sequencing was performed on 50 independent UK MH susceptible samples, with approval by the Leeds East Local Research Ethics Committee and written informed consent from all patients. These samples comprise 30 MHS samples and 20 MHE (responding to halothane but not caffeine) samples; 14 of these MHE samples are from probands who suffered a clinical reaction. The remaining 6 MHE samples are the only available representative from these individual fami-

lies. However, a recent study by our group, using transmission data, supports the classification of MHE samples as affecteds [13]. All 50 of these samples have had the *RYR1* cDNA transcript sequenced and have had no variants detected. There are 30 males and 20 females in the cohort and the ages range from 10-75 years, with a mean of 33 years. The IVCT data for the 50 patients show a median (range) contracture of 0.6 g (0.2 - 4.7 g) at 2% halothane and 0.2 g (0 - 3.6 g) at 2 mM caffeine.

Mutation screening was performed on an additional 410 independent UK MH patients to give a total of 460 independent MH patients represented. Of the 460 independent MH patients, 340 (74%) have an *RYR1* mis-sense change assigned; of these, 298 (65%) co-segregate with disease, 226 (49%) have a functionally characterised *RYR1* change and there are 8 instances of compound heterozygosity with two different *RYR1* changes (one instance each of c.1021G>A/c.7025A>G, c.7063C>T/c.7025A>G, c.7036G>A/c.14817C>A, c.4024A>G/c.4088C>T, c.5441T>A/c.7528T>C and c.10616G>A/c.14210G>A and two instances of 7300G>A/7373G>A). 100 independent MHN samples were also screened.

CACNA1S haplotype analysis was performed on 460 independent UK MH patients, the same as used for mutation screening assays. Population control samples (480) for the haplotype analysis were obtained from a DNA panel of Human Random Controls manufactured by the European Collection of Cell Cultures (ECACC). The DNA is derived from peripheral blood lymphocytes of UK Caucasian donors with informed consent.

CACNA1S sequencing

CACNA1S cDNA sequencing was performed on 50 independent MH susceptible individuals, who did not have an *RYR1* mis-sense change after having previously been sequenced for the *RYR1* cDNA transcript. cDNA prepared from total RNA isolated from muscle biopsy specimens was used to sequence the ~6.16 kb *CACNA1S* cDNA, using 12 overlapping fragments of approximately 700 bp in length, read in both the forward and reverse direction and analysed on an ABI3730.

Mutation analysis

A novel p.Arg174Trp/c.520C>T change in exon 4 causes a loss of an *MspI* site, thus further screening analysis was performed on genomic DNA using the forward primer 5'-CTC AAG CAT GGA CAG GAC AC-3' and reverse primer 5'-AGG AAG GGA GAG GAG AAA GG-3' to generate an amplicon of 279 bp. In the normal (c.520*C) this is cleaved to produce 3 fragments of 49 bp, 67 bp and 163 bp. Cleavage at one of the sites fails to occur in the presence of the mutated allele, c.520*T, thus generating 2 fragments of 116 bp and 163 bp in length.

The previously described *CACNA1S* mutation p.Arg1086His/c.3257G>A in exon 26 was screened for in the full cohort of independent UK MH patients using an assay developed in-house as follows: forward 5' ATG CAC CCT ACC CTA TCT CC-3' and reverse 5'-GGA GCA GGG AGC CTA GTT AC-3' primers generate an amplicon of 998 bp in length. In the normal (c.3257*G) this is cleaved by *HhaI* to produce 3 fragments of 362 bp, 316 bp and 313 bp. Cleavage at one of the sites fails to occur in the presence of the mutated allele, c.3257*A, generating 2 fragments of 629 bp and 362 bp in length.

Haplotype analysis

Haplotype construction

Focusing at the genomic DNA level there are >175 SNPs described across the 73 kb *CACNA1S* gene; predominantly listed in internet databases sources, in particular the CEPH population of the Hap-Map project <http://www.hapmap.org>, and a further 3 identified through in-house *CACNA1S* sequencing. When concentrating on SNPs with a minor allele frequency greater than 0.05 the total number of described SNPs spanning the gene is reduced to 115, 16 of which are located in exons. Using the Tagger software on Haploview we selected eight informative SNPs to span *CACNA1S*. The final list of SNPs chosen is detailed in Table 1.

All SNPs were genotyped using Taqman® methodology. For all SNPs there is an ABI-assay-on-demand available (Table 1). All allelic discrimination assays were carried out on an ABI 7900 according to the manufacturer's instructions. Linkage disequilibrium between the SNPs was calculated using Haploview software [14].

Statistical analysis

The program PHASE (version 2) was used to reconstruct haplotypes from the unphased *CACNA1S* genotype data and to perform case control permutation tests between MHS samples and population control samples [15,16]. PHASE calculates the posterior probability distribution of haplotypes through a Bayesian statistical approach, combining a specified prior for a statistical model for population genetics and likelihood information. The program has a function for case control permutation testing. This tests the null hypothesis that haplotype frequencies are the same in cases and controls, versus the alternative hypothesis that haplotype frequencies are different between the two groups.

The program GENE-BPM, a program designed for use with candidate genes, tests for association of disease with causal variants at an unseen functional polymorphism [17,18]. This program makes use of the expectation that a pair of haplotypes carrying the same disease mutation are more likely to share a more recent common ancestry than

Table 1: Details of the SNPs selected for inclusion in the CACNA1S haplotype analysis

NCBI reference	Location ^a	Chromosomal position ^b	Het ^c	ABI assay number	SNP number
rs1546416	Intron42-43	199276179	0.468	C__2826986_1_	1
rs12029212	Intron32-33	199288242	0.303	C__25474094_10	2
rs7415038	p.Phe801	199305310	0.504	C__3135170_10	3
rs10920105	Intron15-16	199309241	0.468	C__25652884_10	4
rs9427714	p.Gly505	199313734	0.495	C__25652932_10	5
rs2296383	p.Ile199	199327488	0.528	C__15752541_10	6
rs1536129	Intron2-3	199335814	0.439	C__1942693_10	7
rs1325309	Intron1-2	199346081	0.414	C__1942703_20	8

^aLocation of each SNP according to reference sequence

^bChromosomal position according to NCBI reference sequence for chromosome 1

^cHeterozygosity calculated from our data for the 480 population control samples

a random pair of haplotypes in the population and thus are more likely to be similar to each other in terms of their allelic make-up at flanking markers. Furthermore, output of the algorithm can be used to ascertain clusters of haplotypes that are associated with specific causative variants, and to estimate the odds of disease for these unobserved alleles.

Results

CACNA1S sequencing

Full cDNA sequencing identified non-synonymous changes in CACNA1S in 12 individuals, 24% of the MH cases. Sequence changes lead to modifications of amino acids at positions 69 (n = 4), 174 (n = 1), 258 (n = 4), 458 (n = 13), 606 (n = 1), 1541 (n = 4) and 1660 (n = 5) where the number in parentheses represents the total number of MH patients with each change. All are present as heterozygous changes, except the change at position 458 which was also observed in both homozygous forms. However, the changes at positions 1541 and 1660 are previously described polymorphisms (rs3850625 and rs13374149 respectively). The change at position 458 has also been described as polymorphic [5] and indeed was found to be highly variable in our cohort with a heterozygosity of 0.425. The other substitutions detected were in codons determining amino acids that are conserved in rabbit, cat, mouse and zebrafish (NCBI reference sequences NP_001095190, NP_001033694, NP_001074492.1 and NP_999891.1 respectively) and are therefore potentially deleterious mutations rather than infrequent polymorphisms. However, the first change p.Ala69Gly, whilst being detected in 4 MH susceptible individuals, was also detected in 7 from 100 MHN samples, and is therefore

likely to be a polymorphism. Furthermore, the changes p.Gly258Asp and p.Ser606Asn, whilst not being detected in 100 MHN controls, were observed to be frequently discordant with MH status in families. Within the 4 p.Gly258Asp families there are a total of 24 individuals, comprising 5 MHS, 7 MHE and 12 MHN samples, and the p.Gly258Asp change was observed in a total of 3 MHN samples, 2 MHS and 3 MHE samples, whilst the p.Ser606Asn was detected in both the MHE and MHN siblings within a single family. There was no example of compound heterozygosity with these rare changes. These changes can be added to the growing number of non-synonymous changes reported across CACNA1S, over half (10) of which are likely to be polymorphisms (see Table 2).

The final mis-sense variation that was detected, p.Arg174Trp, was found in an MHS sample, was concordant with disease within the family and also not detected in 100 MHN control samples. The mother of the proband was diagnosed MHS through the IVCT, and also had the p.Arg174Trp alteration. A sibling of the proband, diagnosed normal through the IVCT, did not have the p.Arg174Trp change. The MH proband, in whom the p.Arg174Trp was detected, developed intense masseter muscle spasm and generalised muscle rigidity lasting 8 minutes after administration of the inhalation anaesthetics propofol, fentanyl and halothane and the muscle relaxant suxamethonium (1.5 mg/kg). Post-operatively there was severe muscle stiffness that persisted for 2 weeks and a peak serum creatine kinase concentration of 14,500 IU/L (normal < 220 IU/L). The IVCT results for this individual were 0.35 g contracture at 2% halothane and 0.2 g

Table 2: Reported variants in the coding sequence of CACNA1S

Reported mis-sense changes in CACNA1S						
Exon	Nucleotide change ^a	Protein change	Incidence ^b	Population	Disease status ^c	References
1	c.64A>T	p.Glu22Val	Unknown	Unknown	unknown	ss95806
2	c.205C>G	p.Ala69Gly	11	UK	polymorphism	This study (ss43973054)
4	c.520C>T	p.Arg174Trp	1	UK	MH	This study
6	c.773G>A	p.Gly258Asp	4	UK	polymorphism	This study
10	c.1373T>A	p.Leu458His	14	UK & France	polymorphism	This study, 5
11	c.1582C>G	p.Arg528Gly	1	China	HOKPP	[27]
11	c.1583G>A	p.Arg528His	77	Europe, USA, Japan, Korea & china	HOKPP	[28-43]
12	c.1669G>A	p.Arg557His	1	Unknown	unknown	ss6793785
12	c.1817G>A	p.Ser606Asn	1	UK	polymorphism	This study
21	c.2691G>T	p.Arg897Ser	1	France	HOKPP	[44]
26	c.3257G>A	p.Arg1086His	3	USA & France	MH	[5,11,12]
30	c.3684C>G	p.Arg1239Gly	10	USA & Korea	HOKPP	[28,33,42,45,46]
30	c.3685G>A	p.Arg1239His	50	USA, Europe & Japan	HOKPP	[29,33,34,39,42,45,47]
37	c.4475C>A	p.Ala1492Asp	1	Italy	polymorphism	[48]
38	c.4621C>T	p.Arg1541Cys	4	UK	polymorphism	This study (rs3850625)
40	c.4978G>A	p.Arg1660His	5	UK	polymorphism	This study (rs13374149)
44	c.5404T>C	p.Leu1802Ser	Unknown	UK	polymorphism	rs12139527
44	c.5525G>C	p.Glu1842Asp	Unknown	UK	polymorphism	rs1042379

^aNumbering based on cDNA ref: ENST00000263942.

^bTotal number of independent observations.

^cDisease status reported with variant; malignant hyperthermia (MH), and hypokalemic periodic paralysis (HOKPP).

contracture at 2 mM caffeine: laboratory classification (EMHG) MHS.

The cDNA sequencing further identified 3 novel silent changes in the CACNA1S gene. These were located in 2 different exons; p.Leu766/c.2296C>T minor allele frequency of 0.01 and a heterozygosity of 0.02, and p.Ile781/c.2343C>T, with a minor allele frequency of 0.031 and a heterozygosity of 0.06 were located in exon 17 and p.Pro1622/c.4866C>T with a minor allele frequency of

0.208 and a heterozygosity of 0.33 was located in exon 40. There is no significant linkage disequilibrium detected between the markers, with $r^2 = 0$ between 4866*C and both 2296*C and 2343*C, and $r^2 = 0.32$ between the neighbouring markers 2296*C and 2343*C. Linkage disequilibrium was also not detected between these markers and their adjacent markers across CACNA1S, i.e. between 4866*C with either rs3850625*C or rs13374149*G and nor between 2296*C and 2343*C with rs7415038*T or rs1684767*C.

Mutation screening

The p.Arg174Trp change was identified in a single family showing full concordance with disease status and not identified in 100 normal controls. Accordingly we screened for the presence of this site in the full UK cohort of 410 independent MH families. The p.Arg174Trp change was not detected in any other UK family.

The previously described *CACNA1S* mutation p.Arg1086His in exon 26 was screened for in the 460 independent UK MH patients. This change was not detected in any UK MH family, nor the 100 MHN controls.

Haplotype analysis

A total of 460 independent UK MH patients and 480 Caucasian population controls were typed for all eight *CACNA1S* SNP markers. These 8 SNPs were used to reconstruct haplotypes from the unphased data using PHASE and GENEAL. From GENEAL there were a total of 23 haplotypes with an estimated population frequency ≥ 0.01 (1%), and these are detailed in Table 3, along with a breakdown of the haplotype frequencies for each study group (MHS, PC and also the subset of 50 samples that were sequenced for *CACNA1S*) calculated using PHASE. The single SNPs were tested for association with disease using a Spearman rank correlation between MHS samples and PC. There was no evidence for significant associations with any of the markers except p.Ile199, where $p = 0.014$.

Case control permutation testing was performed between MHS samples and the population control samples to test for differences in *CACNA1S* haplotype frequencies using the program PHASE. There was a small but significant difference observed with this comparison ($p = 0.02$), providing evidence for association between MH and *CACNA1S*. However, for the same comparison using the GENEAL program to analysis haplotype relative risk of disease, there was no categorical evidence of *CACNA1S* haplotype association with MH (posterior probability $\hat{p} = 0.46$).

To illustrate the posterior similarities between haplotypes in terms of their risk of carrying causal variants and allelic make-up, a dendrogram can be constructed. Figure 1 presents a dendrogram of the 23 *CACNA1S* haplotypes with estimated relative frequency $\geq 1\%$ from the analysis of MHS cases versus population controls. These 23 haplotypes are coded according to their relative frequency, where 1 represents the most frequent haplotype and 23 the least frequent. The dendrogram shows considerable posterior similarity between haplotypes and demonstrates no apparent clustering of haplotypes, suggesting that there is no clear high risk disease variant. Additionally, the haplotype analysis reveals that there are numerous rela-

tively rare haplotypes (there are only three haplotypes with a frequency $>5\%$ in population controls), suggestive of an elevated degree of haplotype diversity potentially resulting from a high rate of recombination across the locus and a low level of linkage disequilibrium.

To exclude any influence of *RYR1* on the analysis, a case control permutation test in PHASE was also performed between the 480 population control samples and the 50 samples that have been cDNA sequenced for *CACNA1S*. There was no overall significant difference in *CACNA1S* haplotype frequency observed between these groups. The haplotypes H5 and H14 were observed at a noticeably higher frequency in the 50 sequenced samples (0.099 and 0.058 respectively) than the population controls (0.043 and 0.029 respectively) (see Table 3), however given that the haplotype frequencies are relatively small these observations are unlikely to be significant. Further analysis with GENEAL also provided no categorical evidence of *CACNA1S* haplotype association with MH (posterior probability $\hat{p} = 0.415$), suggesting that *CACNA1S* does not play a major role in MH susceptibility, however due to the small number in the cDNA sequenced group this comparison may lack power.

Furthermore, to investigate whether there were any differences in *CACNA1S* haplotype frequencies between MH phenotypes, an additional case control permutation test was performed on the subset of 50 samples that underwent cDNA sequencing between the MHS ($n = 30$) and MHE ($n = 20$) samples using all 8 SNPs. There was no significant difference in *CACNA1S* haplotype frequency observed between the MHS and MHE samples ($p = 0.27$); however, again due to the small numbers in each group this comparison may lack power.

Discussion

As more is being understood about the nature of susceptibility to MH it is becoming increasingly apparent that it is complex and cannot always be simply described as autosomal dominant. There is evidence for variation in clinical severity and IVCT phenotype, resulting from the same mis-sense change in *RYR1* [19,20]. There are also reports of compound heterozygotes in *RYR1* [12,21], unpublished UK observations] and an individual with mutations in both *RYR1* and *CACNA1S* [12]. Furthermore, we have previously demonstrated, using transmission disequilibrium testing, that multiple interacting gene products affect susceptibility to MH [10,22]. Even within families that showed linkage to *RYR1* evidence has been provided for linkage to other loci elsewhere in the genome [10].

Table 3: Details of the 23 CACNA1S haplotypes with an estimated population frequency ≥ 0.01 in at least one group.

Haplotype Name	rs1546416	rs12029212	rs7415038	rs10920105	rs9427714	rs2296383	rs1536129	rs1325309	Estimated haplotype frequencies (Std Error) ^a		
									MHS	PC	50 sequenced samples
H1	2	2	1	1	1	1	1	1	0.084 (0.008)	0.081 (0.007)	0.081 (0.018)
H2	1	2	1	1	1	1	1	1	0.047 (0.007)	0.075 (0.006)	0.055 (0.018)
H3	2	2	2	1	2	2	1	1	0.065 (0.007)	0.059 (0.007)	0.044 (0.014)
H4	2	2	2	2	2	2	2	1	0.05 (0.006)	0.046 (0.006)	0.07 (0.018)
H5	2	1	1	1	1	1	1	1	0.043 (0.008)	0.04 (0.005)	0.099 (0.019)
H6	2	2	2	1	2	2	2	2	0.03 (0.005)	0.05 (0.005)	0.016 (0.009)
H7	1	2	1	1	1	2	2	1	0.03 (0.005)	0.04 (0.004)	0.012 (0.01)
H8	2	2	2	1	2	2	1	2	0.035 (0.005)	0.032 (0.007)	0.035 (0.009)
H9	2	2	2	2	2	1	1	1	0.031 (0.005)	0.036 (0.004)	0.017 (0.012)
H10	2	2	1	1	1	1	1	2	0.036 (0.006)	0.027 (0.005)	0.03 (0.012)
H11	2	2	2	1	2	2	2	1	0.026 (0.005)	0.029 (0.004)	0.029 (0.011)
H12	1	2	1	1	1	1	1	2	0.017 (0.004)	0.032 (0.005)	0.03 (0.012)
H13	1	2	2	1	2	2	1	1	0.026 (0.006)	0.018 (0.003)	0.03 (0.013)
H14	1	2	1	2	2	2	1	2	0.029 (0.004)	0.014 (0.003)	0.058 (0.01)
H15	2	2	2	2	2	2	2	2	0.025 (0.005)	0.02 (0.005)	0.029 (0.015)
H16	1	2	2	2	2	2	2	1	0.02 (0.006)	0.014 (0.004)	0.03 (0.014)
H17	2	2	2	2	2	1	1	2	0.021 (0.005)	0.019 (0.004)	0.015 (0.01)
H18	1	2	1	1	1	2	2	2	0.018 (0.005)	0.017 (0.003)	0.01 (0.009)
H19	2	2	2	2	2	2	1	1	0.017 (0.004)	0.018 (0.003)	0.005 (0.006)
H20	2	1	1	1	1	1	1	2	0.006 (0.003)	0.025 (0.006)	0.026 (0.013)
H21	1	1	2	2	2	1	1	1	0.015 (0.004)	0.01 (0.002)	0.006 (0.007)
H22	1	2	2	2	2	2	1	2	0.017 (0.004)	0.006 (0.002)	0.005 (0.007)
H23	2	2	2	2	2	2	1	2	0.019 (0.004)	0.007 (0.003)	0.015 (0.01)

^aThe estimated haplotype frequencies and standard errors (Std Error) were calculated separately for each of the MHS, Population Control and 50 cDNA CACNA1S sequenced samples using the program PHASE.




Figure 1
Dendrogram of the 23 marker haplotypes with estimated population frequency ≥ 0.01 (1%), to demonstrate similarities between haplotypes in terms of disease risk and marker sharing created from the output of a single run of the MCMC algorithm in GENEPM. Haplotypes are coded according to their relative frequency, thus haplotype 1 is the most common haplotype, and haplotype 23 the least.

This study focused on *CACNA1S* encoding the $\alpha 1$ subunit of the DHPR. In the largest study to date, of 50 MH patients, we identified a single, potentially pathogenic, variant p.Arg174Trp. The p.Arg174Trp change is situated at a site that is conserved in rabbit, cat, mouse, and zebrafish and causes a change in the charge of the amino acid from basic to non-polar. The amino acid in question lies in the S4 segment domain of the DHPR thought to function as a voltage sensor, thus a change in charge may alter the voltage sensor mechanism and consequently disrupt the cellular calcium homeostasis. Further functional work to support these observations would be valuable.

This work also identified two other variants (p.Gly258Asp, p.Ser606Asn) thought to be polymorphic as they do not show disease concordance, but which were not present in control chromosomes. Whilst it is likely that they are indeed polymorphisms, the fact that they lie in conserved regions of the protein and cause a change in the polarity of the amino acid substituted suggests otherwise and there is the potential that they could play a minor role in, or have a modifier effect on, disease phenotype. Since there is evidence that MH may not necessarily be a simple single gene disorder, there is the possibility that both of these changes are present together with an additional major change and in some instances account

for discordancy with disease; i.e. these mutations may be necessary, but not sufficient, to cause MH susceptibility in particular individuals.

Comparison of *CACNA1S* haplotype frequencies between susceptible cases and UK Caucasian population controls identified no significant haplotype frequency differences. Even given that this is the largest standardised and genotyped MH database worldwide, there are a limited number of MH patients, which could reduce the power to detect a significant association between *CACNA1S* haplotype with MH. However, the haplotype analysis does provide some evidence for an elevated haplotype diversity, potentially resulting from the high rate of recombination observed across the locus and a low level of linkage disequilibrium detected, as seen in the present study and consistent with that observed in the HapMap project. Coupling this observation with the now growing number of reported non-pathogenic non-synonymous changes described across *CACNA1S*, it is possible that this locus can tolerate a high degree of variability. This variability could affect the conformation of the DHPR protein, which has implications not only in the E-C coupling of skeletal muscle but also in that of cardiac muscle.

Our data suggest that, whilst *CACNA1S* may play a role in MH manifestation in the UK, it is not a major locus, thereby suggesting that there are other loci with importance in MH susceptibility. As well as the reported linkage to chromosome 1q and 19q there are alternative loci proposed on chromosomes 7q [23] and 17q [24], however no contributory mutations have been identified in these regions. It is highly probable that any novel genes for MH susceptibility will play a minor role. An alternative method to identify genes responsible for MH could be to take a candidate gene approach and focus on genes whose products are directly involved with E-C coupling and Ca²⁺ regulation, for example the other subunits of the DHPR, calmodulin [25] and JP-45 [26].

Conclusion

We have previously proposed that several independent genes can influence the MH phenotype [10,22]. Here we have presented evidence for a novel variant in *CACNA1S* which could have the potential to directly influence MH susceptibility. There was also a possible indirect or modifier effect of *CACNA1S* in a small number of families, likely to cause MH in combination with another, as yet unknown, locus. The evidence for the existence of multiple independent loci that influence MH susceptibility is now increasing and the disorder appears to be more complex than previously thought. To fully comprehend MH and all the gene product interactions we need to identify and characterise all the multiple loci involved.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DC participated in the design of the study, carried out the Taqman[®] genotyping, haplotype analysis and drafted the manuscript. CR and VL carried out the sequencing, screened for the changes Arg1086His and Arg174Trp and performed family studies. AM provided assistance with haplotype analysis. RLR participated in the design of the study. PJH and PMH carried out and determined the IVCT phenotypes. PMH and MAS designed the study, coordinated the study, and participated in the analysis and manuscript preparation. All authors approved the manuscript.

Acknowledgements

Financial support for this project was provided by a grant through the Department of Health Pharmacogenetics Research Programme Grant, and the Big Lottery Fund.

References

1. MacLennan DH, Philips M: **Malignant Hyperthermia.** *Science* 1992, **256**:789-794.
2. Melzer W, Herrmann-Frank A, Luttgau HC: **The role of Ca²⁺ ions in excitation-contraction coupling of skeletal muscle fibres.** *Biochim Biophys Acta* 1995, **1241**:59-116.
3. Yang T, Ta TA, Pessah IN, Allen PD: **Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling.** *J Biol Chem* 2003, **278**:28722-25730.
4. Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT: **Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling.** *Am J Physiol Cell Physiol* 2004, **287**:C1094-1102.
5. Monnier N, Procaccio V, Stieglitz P, Lunardi J: **Malignant hyperthermia susceptibility is associated with a mutation of the α 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.** *Am J Hum Genet* 1997, **60**:1316-1325.
6. Robinson RL, Monnier N, Wolz W, Jung M, Reis A, Nuernberg G, Curran JL, Monsieurs K, Stieglitz P, Heytens L, Fricker R, van Broeckhoven C, Deufel T, Hopkins PM, Lunardi J, Mueller CR: **A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees.** *Hum Mol Genet* 1997, **6**:953-961.
7. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Wortont RG: **Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.** *Nature* 1990, **343**:559-561.
8. McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K: **Localisation of the malignant hyperthermia susceptibility locus to human chromosome 19q12-q13.2.** *Nature* 1990, **343**:562-564.
9. Robinson RL, Carpenter D, Shaw M-A, Halsall PJ, Hopkins PM: **Mutations in RYR1 in malignant hyperthermia and central core disease.** *Hum Mut* 2006, **27**:977-989.
10. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, Iles DE, West SP, Shaw MA: **Multiple interacting gene products may influence susceptibility to malignant hyperthermia.** *Ann Hum Genet* 2000, **64**:307-320.
11. Stewart SL, Hogan K, Rosenberg H, Fletcher JE: **Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia.** *Clin Genet* 2001, **59**:178-184.
12. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J: **Presence of two different**

- genetic traits in malignant hyperthermia families. *Anesthesiology* 2002, **97**:1067-74.**
13. Robinson RL, Carpenter D, Halsall PJ, Iles DE, Booms P, Steele D, Hopkins PM, Shaw M-A: **Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility.** *Br J Anaesth* 2009, **103**:220-225.
 14. Barrett JC, Fry B, Maller J, Daly MJ: **Haploview; analysis and visualization of LD and haplotype maps.** *Bioinformatics* 2005, **21**:263-265.
 15. Stephens M, Smith NJ, Donnelly P: **A new statistical method for haplotype reconstruction from population data.** *Am J Hum Genet* 2001, **68**:978-989.
 16. Stephens M, Donnelly P: **A comparison of Bayesian methods for haplotype reconstruction.** *Am J Hum Genet* 2003, **73**:1162-1169.
 17. Morris AP: **Direct analysis of unphased SNP genotype data in population-based association studies via Bayesian partition modelling of haplotypes.** *Genet Epidemiol* 2005, **29**:91-107.
 18. Morris AP: **A flexible Bayesian framework for modelling haplotype association with disease, allowing for dominance effects of the underlying causative variants.** *Am J Hum Genet* 2006, **79**:679-690.
 19. Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell R, Shaw M-A, Hopkins PM: **RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.** *Hum Mutat* 2002, **20**:88-97.
 20. Carpenter D, Robinson RL, Quinnell R, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS, Shaw MA, Hopkins PM: **Genetic variation in RYR1 and malignant hyperthermia phenotypes.** *Br J Anaesth* 2009, **103**:538-548.
 21. Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, Straub V, Roper H, Rose MR, Brockington M, Kinali M, Manzur A, Robb S, Appleton R, Messina S, D'Amico A, Quinlivan R, Swash M, Müller CR, Brown S, Treves S, Muntoni F: **Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies.** *Brain* 2007, **130**:2024-2036.
 22. Robinson RL, Hopkins PM, Carsana A, Gilly H, Halsall PJ, Heytens L, Islander G, Jurkat-Rott K, Muller CR, Shaw M-A: **Several interacting genes influence the malignant hyperthermia phenotype.** *Hum Genet* 2003, **112**:217-218.
 23. Iles DE, Lehmann-Horn F, Scherer SW, Tsui L-C, Olde Weghuis D, Suijkerbuijk RF, Heytens L, Mikala G, Schwartz A, Ellis FR, Stewart AD, Deufel T, Wieringa B: **Localisation of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families.** *Hum Mol Genet* 1994, **3**:969-975.
 24. Levitt RC, Olkers A, Meyers S, Fletcher JE, Rosenberg H, Iscacs H: **Evidence for the localisation of a malignant hyperthermia susceptibility locus (MHS2) to chromosome 17q.** *Genomics* 1992, **14**:562-566.
 25. Rodney GG, Williams BY, Strasburg GM, Beckingham K, Hamilton SL: **Regulation of RYR1 activity by Ca(2+) and calmodulin.** *Biochem* 2000, **39**:7807-7812.
 26. Gouadon E, Schuhmeier RP, Ursu D, Anderson AA, Treves S, Zorzato F, Lehmann-Hoff F, Melzer W: **A possible role of the junctional face protein JP-45 in modulating Ca2+ release in skeletal muscle.** *J Physiol* 2006, **572**:269-280.
 27. Wang Q, Liu M, Xu C, Tang Z, Liao Y, Du R, Li W, Wu X, Wang X, Liu P, Zhang X, Zhu J, Ren X, Ke T, Wang Q, Yang J: **Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family.** *J Mol Med* 2005, **83**:203-208.
 28. Jurkatt-Rott K, Lehmann-Horn F, Elbaz A, Heine R, Gregg RG, Hogan K, Powers PA, Laple P, Vale-Santos JE, Weissenbach J, Fontaine B: **A calcium channel mutation causing hypokalemic periodic paralysis.** *Hum Mol Genet* 1994, **3**:1415-1419.
 29. Elbaz A, Vale-Santos K, Jurkatt-Rott K, Lapie p, Ophoff RA, Bady B, Links TP, Piussan C, Vila A, Monnier N, Padberg GW, Abe K, Feingold N, Guimaraes J, Wintzen AR, Hoeven JH van der, Saudubray JM, Grunfeld JP, Lenoir G, Nivet H, Echenne B, Frants RR, Fardeau M, Lehmann-Horn F, Fontaine B: **Hypokalemic Periodic Paralysis and the Dihydropyridine Receptor (CACNLI3): Genotype/Phenotype Correlations for two Predominant Mutations and Evidence for the Absence of a Founder Effect in 16 Caucasian Families.** *Am J Hum Genet* 1995, **56**:374-380.
 30. Boerman RH, Ophoff RA, Links TP, van Eijk R, Sandkuijl LA, Elbaz A, Vale-Santos JE, Wintzen AR, van Deutekom JC, Isles DE: **Mutation in DHP receptor alpha 1 subunit (CACNLI3) gene in a Dutch family with hypokalemic periodic paralysis.** *J Med Genet* 1995, **32**:44-47.
 31. Grossen CLS, Esteban J, McKenna-Yasek D, Gusella JF, Brown RH: **Hypokalemic periodic paralysis mutations: Confirmation of mutation and analysis of founder effect.** *Neuromuscul Disord* 1996, **6**:27-31.
 32. Ikeda Y, Watanabe M, Shoji M: **Mutation analysis of the CACNLI3 gene in Japanese hypokalemic periodic paralysis families.** *Jpn J Clin Med* 1997, **55**:3247-3252.
 33. Fouad G, Dalakas M, Servidei S, Mendell JR, Bergh P Van den, Angelini C, Alderson K, Griggs RC, Tawil R, Gregg R, Hogan K, Powers PA, Weinberg N, Malonee W, Ptáček LJ: **Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis.** *Neuromuscul Disord* 1997, **7**:33-38.
 34. Sillen A, Sorensen T, Kantola I, Friis ML, Gustavson K, Wadelius C: **Identification of mutations in the CACNLI3 gene in 13 families of Scandinavian origin having hypokalemic periodic paralysis and evidence of a founder effect in Danish families.** *Am J Med Genet* 1997, **69**:102-106.
 35. Tricarico D, Servidei S, Tonali P, Jurkat-Rott K, Camerino DC: **Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis.** *J Clin Invest* 1999, **103**:675-682.
 36. Dominguez-Moran JA, Baron M, de Blas G, Orensanz LM, Jimenez-Escrig A: **Clinical-molecular study of a family with essential tremor, late onset seizures and periodic paralysis.** *Seizure* 2000, **7**:493-497.
 37. Wada T, Yachie A, Fujita S, Takei K, Sumita R, Ichihara T, Koizumi S: **Hypokalemic periodic paralysis and mutations in the CACNLI3 gene: Case study in a Japanese family.** *Pediatr Int* 2000, **42**:325-327.
 38. Kim SH, Kim UK, Chae JJ, Kim DJ, Oh HY, Kim BJ, Lee CC: **Identification of mutations including de novo mutations in Korean patients with hypokalaemic periodic paralysis.** *Nephrol Dial Transplant* 2001, **16**:939-944.
 39. Davies NP, Eunson LH, Samuel M, Hanna MG: **Sodium channel gene mutations in hypokalemic periodic paralysis: An uncommon cause in the UK.** *Neurology* 2001, **57**:1323-1325.
 40. Caciotta A, Morrone A, Domenici R, Donati MA, Zammarchi E: **Severe prognosis in a large family with hypokalemic periodic paralysis.** *Muscle Nerve* 2003, **27**:165-169.
 41. Kawamura S, Ikeda Y, Tomita K, Watanabe N, Seki K: **A Family of Hypokalemic Periodic Paralysis with CACNA1S Gene Mutation Showing Incomplete Penetrance in Women.** *Intern Med* 2004, **43**:218-222.
 42. Miller TM, da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, McManis P, Griggs RC, Angelini C, Servidei S, Petajan J, Dalakas MC, Ranum LP, Fu YH, Ptáček LJ: **Correlating phenotype and genotype in the periodic paralyses.** *Neurology* 2004, **63**:1647-1655.
 43. Lin SH, Hsu YD, Cheng NL, Kao MC: **Skeletal Muscle Dihydropyridine-Sensitive Calcium Channel (CACNA1S) Gene Mutations in Chinese Patients with Hypokalemic Periodic Paralysis.** *Am J Med Sci* 2005, **329**:66-70.
 44. Chabrier S, Monnier N, Lunardi J: **Early onset of hypokalaemic periodic paralysis caused by a novel mutation in the CACNA1S gene.** *J Med Genet* 2008, **45**:686-688.
 45. Ptáček LJ, Tawil R, Griggs RC, Engel AG, Layzer RB, Kwiecinski H, McManis PG, Santiago L, Moore M, Fouad G, Bradley P, Leppert MF: **Dihydropyridine receptor mutations cause hypokalemic periodic paralysis.** *Cell* 1994, **77**:863-868.
 46. Kim JB, Lee KY, Hur JK: **A Korean Family of Hypokalemic Periodic Paralysis with Mutation in a Voltage-gated Calcium Channel (R1239G).** *J Korean Med Sci* 2005, **20**:162-165.
 47. Kusumi M, Kumada H, Adachi Y, Nakashima K: **Muscle weakness in a Japanese family of Arg1239His mutation hypokalemic periodic paralysis.** *Psychiatry Clin Neurosci* 2001, **55**:539-541.
 48. Carsana A, Fortunato G, de Sarno C, Brancadoro V, Salvatore F: **Identification of new mutations in the CACNA1S gene.** *Clin Chem Lab Med* 2003, **41**:20-22.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/10/104/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

